Portal de Periódicos da CAPES

Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry

2017; Elsevier BV; Volume: 45; Linguagem: Inglês

10.1016/j.parkreldis.2017.09.018

1873-5126

Angelo Antonini, Werner Poewe, К. Ray Chaudhuri, Robert Jech, Barbara Pickut, Zvezdan Pirtošek, József Attila Szász, Francesc Valldeoriola, Christian Winkler, Lars Bergmann, Ashley Yegin, Koray Onuk, David Barch, Per Odin, Ene Amalia, G. Arnold, Ovidiu Băjenaru, Bruno Bergmans, Kari Anne Bjørnarå, Jeff Blackie, Matthias Bode, Paul Bourgeois, Stephan Bohlhalter, Ioan Buraga, Pierre R. Burkhard, Philippe Busson, Matilde Calopa, Jesper O. Clausen, Erik Hvid Danielsen, Luc Defebvre, Valérie Delvaux, Sophie Dethy, Espen Dietrichs, Oriol de Fábregues, Ransmayr Gerhard, Graziano Gusmaroli, Kirsten Hahn, Björn Hauptmann, Tove Henriksen, Jorge Hernández‐Vara, Anne Jeanjean, Michaela Kaiserová, Jan Kassubek, Thomas Kimber, Spyridon Konitsiotis, Rejko Krüger, Jaime Kulisevsky, Jo Leenders, Christofer Lundqvist, Frédéric Magné, Pietro Marano, Ivan Milanov, Nicola Modugno, Anjum Misbahuddin, Martin Nevrlý, Zikos Panayiotis, Kenn Freddy Pedersen, Stephen Wørlich Pedersen, Lăcrămioara Perju‐Dumbravă, Mirthe M. Ponsen, Bogdan Ovidiu Popescu, Michel Rijntjes, Víctor Puente, Christoph Redecker, Christoph Schrader, Mariachiara Sensi, Mihaela Simu, Cleanthe Spanaki, Alexander Storch, Anette Storstein, Volker Tomantschger, Chris van der Linden, Teus van Laar, François Viallet, Tatiana Witjas, Martin Wolz, Maurizio Zibetti, Michel Van Zandijcke,

Restless Legs Syndrome Research

This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa intestinal gel (LCIG) treatment in advanced Parkinson's disease (PD) patients under routine clinical care.Motor fluctuations, dyskinesia, non-motor symptoms, quality of life, and safety were evaluated. Observations were fully prospective for treatment-naïve patients (60% of patients) and partially retrospective for patients with ≤12 months of pre-treatment with LCIG (40% of patients). Hours of "On" and "Off" time were assessed with a modified version of the Unified Parkinson's Disease Rating Scale part IV items 32 and 39.Overall, 375 patients were enrolled by 75 movement disorder centers in 18 countries and 258 patients completed the registry. At 24 months LCIG treatment led to significant reductions from baseline in "Off" time (hours/day) (mean ± SD = -4.1 ± 3.5, P < 0.001), "On" time with dyskinesia (hours/day) (-1.1 ± 4.8, P = 0.006), Non-Motor Symptom Scale total (-16.7 ± 43.2, P < 0.001) and individual domains scores, and Parkinson's Disease Questionnaire-8 item total score (-7.1 ± 21.0, P < 0.001). Adverse events deemed to have a possible/probable causal relationship to treatment drug/device were reported in 194 (54%) patients; the most frequently reported were decreased weight (6.7%), device related infections (5.9%), device dislocations (4.8%), device issues (4.8%), and polyneuropathy (4.5%).LCIG treatment led to sustained improvements in motor fluctuations, non-motor symptoms particularly sleep/fatigue, mood/cognition and gastrointestinal domains, as well as quality of life in advanced PD patients over 24 months. Safety events were consistent with the established safety profile of LCIG.